Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial

Amar U. Kishan; Nicholas Marco; Ting Martin Ma; Michael L. Steinberg; Ankush Sachdeva; Minsong Cao; Leslie K. Ballas; Emily Rietdorf; Donatello Telesca; Joanne B. Weidhaas

Clinical and Translational Radiation Oncology (Mar 2023)

Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial

Amar U. Kishan,
Nicholas Marco,
Ting Martin Ma,
Michael L. Steinberg,
Ankush Sachdeva,
Minsong Cao,
Leslie K. Ballas,
Emily Rietdorf,
Donatello Telesca,
Joanne B. Weidhaas

Affiliations

Amar U. Kishan: University of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA
Nicholas Marco: University of California, Department of Statistics, Los Angeles, CA 90025, USA
Ting Martin Ma: University of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA
Michael L. Steinberg: University of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA
Ankush Sachdeva: University of California, Institute of Urologic Oncology, Los Angeles, CA 90025, USA
Minsong Cao: University of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA
Leslie K. Ballas: Cedars Sinai, Department of Radiation Oncology, Los Angeles, CA 90048, USA
Emily Rietdorf: University of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA
Donatello Telesca: University of California, Department of Statistics, Los Angeles, CA 90025, USA
Joanne B. Weidhaas: University of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA; Corresponding author.

Journal volume & issue: Vol. 39
p. 100594

Abstract

Read online

Predictors of genitourinary toxicity after post-prostatectomy radiotherapy remain elusive. A previously defined germline DNA signature (PROSTOX) has shown predictive ability for late grade ≥ 2 GU toxicity after intact prostate stereotactic body radiotherapy. We explore whether PROSTOX would predict toxicity among patients receiving post-prostatectomy SBRT on a phase II clinical trial.

Published in Clinical and Translational Radiation Oncology

ISSN: 2405-6308 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/clinical-and-translational-radiation-oncology

About the journal

Abstract

Keywords